BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sutter O, Calvo J, N'Kontchou G, Nault JC, Ourabia R, Nahon P, Ganne-Carrié N, Bourcier V, Zentar N, Bouhafs F, Sellier N, Diallo A, Seror O. Safety and Efficacy of Irreversible Electroporation for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: A Retrospective Single-Center Case Series. Radiology 2017;284:877-86. [PMID: 28453431 DOI: 10.1148/radiol.2017161413] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 13.8] [Reference Citation Analysis]
Number Citing Articles
1 Kalra N, Gupta P, Gorsi U, Bhujade H, Chaluvashetty SB, Duseja A, Singh V, Dhiman RK, Chawla YK, Khandelwal N. Irreversible Electroporation for Unresectable Hepatocellular Carcinoma: Initial Experience. Cardiovasc Intervent Radiol. 2019;42:584-590. [PMID: 30697637 DOI: 10.1007/s00270-019-02164-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
2 Fang C, Kibriya N, Heaton ND, Prachalias A, Srinivasan P, Menon K, Peddu P. Safety and efficacy of irreversible electroporation treatment in hepatobiliary and pancreatic tumours: a single-centre experience. Clin Radiol 2021;76:599-606. [PMID: 33934875 DOI: 10.1016/j.crad.2021.03.020] [Reference Citation Analysis]
3 Lyu C, Lopez-Ichikawa M, Rubinsky B, Chang TT. Normal and fibrotic liver parenchyma respond differently to irreversible electroporation. HPB (Oxford) 2019;21:1344-53. [PMID: 30879992 DOI: 10.1016/j.hpb.2019.01.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Su TH, Hsu SJ, Kao JH. Paradigm shift in the treatment options of hepatocellular carcinoma. Liver Int 2021. [PMID: 34515412 DOI: 10.1111/liv.15052] [Reference Citation Analysis]
5 Cohen EI, Field D, Lynskey GE, Kim AY. Technology of irreversible electroporation and review of its clinical data on liver cancers. Expert Rev Med Devices 2018;15:99-106. [PMID: 29307242 DOI: 10.1080/17434440.2018.1425612] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
6 Gans JH, Lipman J, Golowa Y, Kinkhabwala M, Kaubisch A. Hepatic Cancers Overview: Surgical and Chemotherapeutic Options, How Do Y-90 Microspheres Fit in? Seminars in Nuclear Medicine 2019;49:170-81. [DOI: 10.1053/j.semnuclmed.2019.01.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
7 Thompson SM, Wells ML, Andrews JC, Ehman EC, Menias CO, Hallemeier CL, Roberts LR, Venkatesh SK. Venous invasion by hepatic tumors: imaging appearance and implications for management. Abdom Radiol (NY) 2018;43:1947-67. [PMID: 28929197 DOI: 10.1007/s00261-017-1298-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
8 Chai W, Zhao Q, Kong D, Jiang T. Percutaneous Laser Ablation of Hepatic Tumors Located in the Portacaval Space: Preliminary Results. Lasers Surg Med. 2019;51:866-873. [PMID: 31286541 DOI: 10.1002/lsm.23123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Ridouani F, Ghosn M, Cornelis F, Petre EN, Hsu M, Moskowitz CS, Kingham PT, Solomon SB, Srimathveeravalli G. Ablation Zone Involution of Liver Tumors Is Faster in Patients Treated with Irreversible Electroporation Than Microwave Ablation. Medicina (Kaunas) 2021;57:877. [PMID: 34577800 DOI: 10.3390/medicina57090877] [Reference Citation Analysis]
10 Chai W, Xie L, Zhao Q, Cheng C, Tian G, Jiang T, Wu P. Ultrasound and Contrast-enhanced Ultrasound Findings after Percutaneous Irreversible Electroporation of Hepatic Malignant Tumors. Ultrasound Med Biol 2020;46:620-9. [PMID: 31924420 DOI: 10.1016/j.ultrasmedbio.2019.12.012] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Blaise L, Pereira H, Vilgrain V, Sutter O, Gigante E, Walter A, Ganne-Carrié N, Nahon P, Bouattour M, Dioguardi Burgio M, Grando V, Nkontchou G, Seror O, Nault JC. Percutaneous ablation for locally advanced hepatocellular carcinoma with tumor portal invasion. Clin Res Hepatol Gastroenterol 2021;45:101731. [PMID: 34139320 DOI: 10.1016/j.clinre.2021.101731] [Reference Citation Analysis]
12 Zheng L, Feng H, Yin L, Wang J, Zhou W, Tang S, Li M. Study on the Correlation Factors of Tumour Prognosis after Intravascular Interventional Therapy. J Healthc Eng 2021;2021:6940056. [PMID: 34745508 DOI: 10.1155/2021/6940056] [Reference Citation Analysis]
13 Pan F, Do TD, Vollherbst DF, Pereira PL, Richter GM, Faerber M, Weiss KH, Mehrabi A, Kauczor HU, Sommer CM. Percutaneous Irreversible Electroporation for Treatment of Small Hepatocellular Carcinoma Invisible on Unenhanced CT: A Novel Combined Strategy with Prior Transarterial Tumor Marking. Cancers (Basel) 2021;13:2021. [PMID: 33922067 DOI: 10.3390/cancers13092021] [Reference Citation Analysis]
14 Stillström D, Beermann M, Engstrand J, Freedman J, Nilsson H. Initial experience with irreversible electroporation of liver tumours. Eur J Radiol Open 2019;6:62-7. [PMID: 30723754 DOI: 10.1016/j.ejro.2019.01.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
15 Gallinato O, de Senneville BD, Seror O, Poignard C. Numerical workflow of irreversible electroporation for deep-seated tumor. Phys Med Biol 2019;64:055016. [PMID: 30669121 DOI: 10.1088/1361-6560/ab00c4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
16 Kloeckner R, Galle PR, Bruix J. Local and Regional Therapies for Hepatocellular Carcinoma. Hepatology 2021;73 Suppl 1:137-49. [PMID: 32557715 DOI: 10.1002/hep.31424] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
17 Qian K, Zhang F, Allison SK, Zheng C, Yang X. Image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: Current status. J Interv Med 2021;4:1-7. [PMID: 34805939 DOI: 10.1016/j.jimed.2020.10.008] [Reference Citation Analysis]
18 Reig M, Forner A, Ávila MA, Ayuso C, Mínguez B, Varela M, Bilbao I, Bilbao JI, Burrel M, Bustamante J, Ferrer J, Gómez MÁ, Llovet JM, De la Mata M, Matilla A, Pardo F, Pastrana MA, Rodríguez-Perálvarez M, Tabernero J, Urbano J, Vera R, Sangro B, Bruix J. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Med Clin (Barc) 2021;156:463.e1-463.e30. [PMID: 33461840 DOI: 10.1016/j.medcli.2020.09.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Fang Z, Mao H, Moser MAJ, Zhang W, Qian Z, Zhang B. Irreversible Electroporation Enhanced by Radiofrequency Ablation: An In Vitro and Computational Study in a 3D Liver Tumor Model. Ann Biomed Eng 2021. [PMID: 33594637 DOI: 10.1007/s10439-021-02734-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Biondetti P, Saggiante L, Ierardi AM, Iavarone M, Sangiovanni A, Pesapane F, Fumarola EM, Lampertico P, Carrafiello G. Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC. Cancers (Basel) 2021;13:5797. [PMID: 34830949 DOI: 10.3390/cancers13225797] [Reference Citation Analysis]
21 Gerena M, Molvar C, Masciocchi M, Nandwana S, Sabottke C, Spieler B, Sharma R, Tsai L, Kielar A. LI-RADS treatment response assessment of combination locoregional therapy for HCC. Abdom Radiol (NY) 2021;46:3634-47. [PMID: 34120207 DOI: 10.1007/s00261-021-03165-x] [Reference Citation Analysis]
22 Viveiros P, Riaz A, Lewandowski RJ, Mahalingam D. Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC). Cancers (Basel) 2019;11:E1085. [PMID: 31370248 DOI: 10.3390/cancers11081085] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
23 Heverhagen JT, Kudrnová S. Subcentimeter Hepatocellular Carcinoma: A New Paradigm for Treatment with Percutaneous Radiofrequency Ablation? Radiology 2018;288:887-8. [PMID: 29916779 DOI: 10.1148/radiol.2018180977] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
24 Yu M, Li S. Irreversible electroporation for liver cancer ablation: A meta analysis. Eur J Surg Oncol 2021:S0748-7983(21)00981-1. [PMID: 35012834 DOI: 10.1016/j.ejso.2021.12.015] [Reference Citation Analysis]
25 Liu ZG, Chen XH, Yu ZJ, Lv J, Ren ZG. Recent progress in pulsed electric field ablation for liver cancer. World J Gastroenterol 2020; 26(24): 3421-3431 [PMID: 32655266 DOI: 10.3748/wjg.v26.i24.3421] [Cited by in CrossRef: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Pillai AA, Ramanathan M, Kulik L. Locoregional Therapies for Hepatocellular Carcinoma: What Has Changed in the Past Ten Years? Clin Liver Dis 2020;24:681-700. [PMID: 33012453 DOI: 10.1016/j.cld.2020.07.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Devcic Z, Elboraey M, Vidal L, Mody K, Harnois D, Patel T, Toskich BB. Individualized Ablation of Hepatocellular Carcinoma: Tailored Approaches across the Phenotype Spectrum. Semin Intervent Radiol 2019;36:287-97. [PMID: 31680719 DOI: 10.1055/s-0039-1698755] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Arellano RS. What's New in Percutaneous Ablative Strategies for Hepatocellular Carcinoma and Colorectal Hepatic Metastases? 2020 Update. Curr Oncol Rep 2020;22:105. [PMID: 32725433 DOI: 10.1007/s11912-020-00967-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Tameez Ud Din A, Tameez-Ud-Din A, Chaudhary FMD, Chaudhary NA, Siddiqui KH. Irreversible Electroporation For Liver Tumors: A Review Of Literature. Cureus 2019;11:e4994. [PMID: 31497425 DOI: 10.7759/cureus.4994] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
30 Gupta P, Maralakunte M, Sagar S, Kumar-M P, Bhujade H, Chaluvashetty SB, Kalra N. Efficacy and safety of irreversible electroporation for malignant liver tumors: a systematic review and meta-analysis. Eur Radiol 2021;31:6511-21. [PMID: 33638687 DOI: 10.1007/s00330-021-07742-y] [Reference Citation Analysis]
31 Pompili M, Francica G. Irreversible electroporation for hepatic tumors. J Ultrasound 2019;22:1-3. [PMID: 30840216 DOI: 10.1007/s40477-019-00367-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Edhemovic I, Brecelj E, Cemazar M, Boc N, Trotovsek B, Djokic M, Dezman R, Ivanecz A, Potrc S, Bosnjak M, Markelc B, Kos B, Miklavcic D, Gasljevic G, Sersa G. Intraoperative electrochemotherapy of colorectal liver metastases: A prospective phase II study. Eur J Surg Oncol 2020;46:1628-33. [PMID: 32387070 DOI: 10.1016/j.ejso.2020.04.037] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
33 Djokic M, Dezman R, Cemazar M, Stabuc M, Petric M, Smid LM, Jansa R, Plesnik B, Bosnjak M, Tratar UL, Trotovsek B, Kos B, Miklavcic D, Sersa G, Popovic P. Percutaneous image guided electrochemotherapy of hepatocellular carcinoma: technological advancement. Radiol Oncol 2020;54:347-52. [PMID: 32562533 DOI: 10.2478/raon-2020-0038] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
34 Huber TC, Bochnakova T, Koethe Y, Park B, Farsad K. Percutaneous Therapies for Hepatocellular Carcinoma: Evolution of Liver Directed Therapies. J Hepatocell Carcinoma 2021;8:1181-93. [PMID: 34589446 DOI: 10.2147/JHC.S268300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Nahon P, Vibert E, Nault JC, Ganne-Carrié N, Ziol M, Seror O. Optimizing curative management of hepatocellular carcinoma. Liver Int 2020;40 Suppl 1:109-15. [PMID: 32077602 DOI: 10.1111/liv.14345] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
36 Pan L, Sun C, Zhou K, Figini M, Wang B, Shangguan J, Hu S, Yang J, Xing W, Wang J, Velichko Y, Yaghmai V, Zhang Z. Transcatheter Intraarterial Perfusion MRI Approaches to Differentiate Reversibly Electroporated Penumbra From Irreversibly Electroporated Zones in Rabbit Liver. Acad Radiol 2020;27:1727-33. [PMID: 32033861 DOI: 10.1016/j.acra.2020.01.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
37 Bäumler W, Wiggermann P, Lürken L, Dollinger M, Stroszczynski C, Beyer LP, Schicho A. Early Detection of Local Tumor Progression after Irreversible Electroporation (IRE) of a Hepatocellular Carcinoma Using Gd-EOB-DTPA-Based MR Imaging at 3T. Cancers (Basel) 2021;13:1595. [PMID: 33808336 DOI: 10.3390/cancers13071595] [Reference Citation Analysis]
38 Zhou Y, Yang Y, Zhou B, Wang Z, Zhu R, Chen X, Ouyang J, Li Q, Zhou J. Challenges Facing Percutaneous Ablation in the Treatment of Hepatocellular Carcinoma: Extension of Ablation Criteria. J Hepatocell Carcinoma 2021;8:625-44. [PMID: 34189133 DOI: 10.2147/JHC.S298709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Brock RM, Beitel-White N, Davalos RV, Allen IC. Starting a Fire Without Flame: The Induction of Cell Death and Inflammation in Electroporation-Based Tumor Ablation Strategies.Front Oncol. 2020;10:1235. [PMID: 32850371 DOI: 10.3389/fonc.2020.01235] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
40 Nault JC, Nahon P, Séror O. Percutaneous ablation for HCC eligible to transplantation: providing more opportunities of remission in the context of graft shortage. Hepatobiliary Surg Nutr 2018;7:302-4. [PMID: 30221161 DOI: 10.21037/hbsn.2018.06.01] [Reference Citation Analysis]
41 Piñero F, Tanno M, Aballay Soteras G, Tisi Baña M, Dirchwolf M, Fassio E, Ruf A, Mengarelli S, Borzi S, Fernández N, Ridruejo E, Descalzi V, Anders M, Mazzolini G, Reggiardo V, Marciano S, Perazzo F, Spina JC, McCormack L, Maraschio M, Lagues C, Gadano A, Villamil F, Silva M, Cairo F, Ameigeiras B; Argentinean Association for the Study of Liver Diseases (A.A.E.E.H). Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. Ann Hepatol 2020;19:546-69. [PMID: 32593747 DOI: 10.1016/j.aohep.2020.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
42 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1974] [Article Influence: 530.5] [Reference Citation Analysis]
43 Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, Lencioni R. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18:293-313. [PMID: 33510460 DOI: 10.1038/s41575-020-00395-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
44 Sugimoto K, Kakimi K, Takeuchi H, Fujieda N, Saito K, Sato E, Sakamaki K, Moriyasu F, Itoi T. Irreversible Electroporation versus Radiofrequency Ablation: Comparison of Systemic Immune Responses in Patients with Hepatocellular Carcinoma. J Vasc Interv Radiol. 2019;30:845-853.e6. [PMID: 31126596 DOI: 10.1016/j.jvir.2019.03.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
45 Dalia A, Essandoh M, Poorsattar S, Kothari P, O'brien EO, Dimitrov T, Rudnick D, Hussain N, Cronin B. The Year in Electrophysiology: Selected Highlights from 2019. Journal of Cardiothoracic and Vascular Anesthesia 2020;34:1406-15. [DOI: 10.1053/j.jvca.2020.01.060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Guo X, Du F, Liu Q, Guo Y, Wang Q, Huang W, Wang Z, Ding X, Wu Z. Immunological effect of irreversible electroporation on hepatocellular carcinoma. BMC Cancer 2021;21:443. [PMID: 33882892 DOI: 10.1186/s12885-021-08176-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. [PMID: 33479224 DOI: 10.1038/s41572-020-00240-3] [Cited by in Crossref: 96] [Cited by in F6Publishing: 108] [Article Influence: 96.0] [Reference Citation Analysis]
48 Freeman E, Cheung W, Kavnoudias H, Majeed A, Kemp W, Roberts SK. Irreversible Electroporation For Hepatocellular Carcinoma: Longer-Term Outcomes At A Single Centre. Cardiovasc Intervent Radiol 2021;44:247-53. [PMID: 33051707 DOI: 10.1007/s00270-020-02666-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
49 Akhan O, Sarıkaya Y, Köksal A, Ünal E, Çiftçi T, Akıncı D. Irreversible Electroporation of Recurrent Hepatocellular Carcinoma After Liver Transplantation: Report of Two Cases. Cardiovasc Intervent Radiol 2021;44:807-11. [PMID: 33655357 DOI: 10.1007/s00270-021-02784-7] [Reference Citation Analysis]
50 Loriaud A, Denys A, Seror O, Vietti Violi N, Digklia A, Duran R, Trillaud H, Hocquelet A. Hepatocellular carcinoma abutting large vessels: comparison of four percutaneous ablation systems. Int J Hyperthermia 2018;34:1171-8. [PMID: 29457510 DOI: 10.1080/02656736.2018.1440017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
51 Philips CA, Rajesh S, Nair DC, Ahamed R, Abduljaleel JK, Augustine P. Hepatocellular Carcinoma in 2021: An Exhaustive Update. Cureus 2021;13:e19274. [PMID: 34754704 DOI: 10.7759/cureus.19274] [Reference Citation Analysis]
52 Sugimoto K, Abe M, Yoshimasu Y, Takeuchi H, Kasai Y, Itoi T. Irreversible electroporation of hepatocellular carcinoma: the role of ultrasonography. Ultrasonography 2020;39:229-37. [PMID: 32450674 DOI: 10.14366/usg.20023] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Choi JW, Lee JM, Kim HC, Lee M, Hur S, Jae HJ, Chung JW. Iatrogenic Arterioportal Fistula Caused by Radiofrequency Ablation of Hepatocellular Carcinoma: Clinical Course and Treatment Outcomes. J Vasc Interv Radiol 2020;31:728-36. [PMID: 32229078 DOI: 10.1016/j.jvir.2019.10.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Berman ZT, Newton I. Diagnosis, Staging, and Patient Selection for Locoregional Therapy to Treat Hepatocellular Carcinoma. Semin Intervent Radiol 2020;37:441-7. [PMID: 33328699 DOI: 10.1055/s-0040-1719185] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Livia C, Sugrue A, Witt T, Polkinghorne MD, Maor E, Kapa S, Lehmann HI, DeSimone CV, Behfar A, Asirvatham SJ, McLeod CJ. Elimination of Purkinje Fibers by Electroporation Reduces Ventricular Fibrillation Vulnerability. J Am Heart Assoc 2018;7:e009070. [PMID: 30371233 DOI: 10.1161/JAHA.118.009070] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 6.3] [Reference Citation Analysis]
56 Kim CG, Lee HW, Choi HJ, Lee JI, Kim SU, Park JY, Kim DY, Ahn SH, Han KH, Kim HS, Kim KH, Choi SJ, Kim Y, Lee KS, Kim GM, Kim MD, Won JY, Lee DY, Kim BK. Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation. Cancer Med. 2019;8:5023-5032. [PMID: 31290618 DOI: 10.1002/cam4.2417] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
57 Yang PC, Chen YJ, Li XY, Hsiao CY, Cheng BB, Gao Y, Zhou BZ, Chen SY, Hu SQ, Zeng Q, Huang KW. Irreversible Electroporation Treatment With Intraoperative Biliary Stenting for Unresectable Perihilar Cholangiocarcinoma: A Pilot Study. Front Oncol 2021;11:710536. [PMID: 34277454 DOI: 10.3389/fonc.2021.710536] [Reference Citation Analysis]
58 Figini M, Zhou K, Pan L, Sun C, Wang B, Hu S, Yang J, Shangguan J, Eresen A, Velichko Y, Yaghmai V, Zhang Z. Transcatheter intra-arterial perfusion (TRIP)-MRI biomarkers help detect immediate response to irreversible electroporation of rabbit VX2 liver tumor. Magn Reson Med. 2020;84:365-374. [PMID: 31850550 DOI: 10.1002/mrm.28104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
59 Lochab V, Jones TH, Alkandry E, West JD, Abdel-Rahman MH, Subramaniam VV, Prakash S. Evaluation of electrical properties of ex vivo human hepatic tissue with metastatic colorectal cancer. Physiol Meas 2020;41:085005. [PMID: 32909548 DOI: 10.1088/1361-6579/abaa55] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
60 Truong VG, Kim H, Park JS, Tran VN, Kang HW. Multiple cylindrical interstitial laser ablations (CILAs) of porcine pancreas in ex vivo and in vivo models. Int J Hyperthermia 2021;38:1313-21. [PMID: 34472992 DOI: 10.1080/02656736.2021.1972171] [Reference Citation Analysis]
61 Bailey CW, Sydnor MK Jr. Current State of Tumor Ablation Therapies. Dig Dis Sci 2019;64:951-8. [PMID: 30859403 DOI: 10.1007/s10620-019-05514-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
62 Gallinato O, de Senneville BD, Seror O, Poignard C, Hubert F. Numerical modelling challenges for clinical electroporation ablation technique of liver tumors. Math Model Nat Phenom 2020;15:11. [DOI: 10.1051/mmnp/2019037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
63 Matthew Hawkins C, Towbin AJ, Roebuck DJ, Monroe EJ, Gill AE, Thakor AS, Towbin RB, Cahill AM, Lungren MP. Role of interventional radiology in managing pediatric liver tumors: Part 2: percutaneous interventions. Pediatr Radiol 2018;48:565-80. [DOI: 10.1007/s00247-018-4072-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
64 Dai Z, Wang Z, Lei K, Liao J, Peng Z, Lin M, Liang P, Yu J, Peng S, Chen S, Kuang M. Irreversible electroporation induces CD8+ T cell immune response against post-ablation hepatocellular carcinoma growth. Cancer Lett 2021;503:1-10. [PMID: 33444692 DOI: 10.1016/j.canlet.2021.01.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
65 Young S, Taylor AJ, Sanghvi T. Post Locoregional Therapy Treatment Imaging in Hepatocellular Carcinoma Patients: A Literature-based Review. J Clin Transl Hepatol 2018;6:189-97. [PMID: 29951364 DOI: 10.14218/JCTH.2017.00059] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 2.8] [Reference Citation Analysis]
66 Lee KW, Lee JM, Choi HS, Kim ES, Keum B, Seo YS, Jeen YT, Um SH, Lee HS, Chun HJ, Kim CD, Oh CH, Kim HB. Novel Ablation Therapy Using Endoscopic Irreversible Electroporation in the Bile Duct: A Pilot Animal Study. Clin Endosc 2021;54:413-9. [PMID: 33076633 DOI: 10.5946/ce.2020.126] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Wu LM, Zhang LL, Chen XH, Zheng SS. Is irreversible electroporation safe and effective in the treatment of hepatobiliary and pancreatic cancers? Hepatobiliary Pancreat Dis Int. 2019;18:117-124. [PMID: 30655073 DOI: 10.1016/j.hbpd.2019.01.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
68 Wang W, Hou S, Ni J, Sun H, Jiang X, Chen Y, Xu L. Effectiveness and safety of irreversible electroporation for recurrent hepatocellular carcinoma ineligible for thermal ablation after surgery. J Interv Med 2020;3:151-5. [PMID: 34805927 DOI: 10.1016/j.jimed.2020.07.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]